scholarly journals Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B

10.19082/2466 ◽  
2016 ◽  
Vol 8 (6) ◽  
pp. 2466-2474
Author(s):  
Mostafa Mahabadi ◽  
Seyed Moayed Alavian ◽  
Mehdi Norouzi ◽  
Hossein Keyvani ◽  
Mahmood Mahmoudi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Reverse Transcriptase ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Mutational Analysis ◽  
Surface Proteins ◽  
Antiviral Therapies ◽  
Partial Virological Response

Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment

2020 ◽  
Vol 27 (7) ◽  
pp. 731-738 ◽  
Author(s):  
Ya‐Chao Tao ◽  
Meng‐Lan Wang ◽  
Dong‐Mei Zhang ◽  
Dong‐Bo Wu ◽  
Yong‐Hong Wang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Drug Administration ◽  
Virological Response ◽  
Optimal Drug ◽  
Partial Virological Response

Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy

2016 ◽  
Vol 50 (4) ◽  
pp. 338-344 ◽  
Author(s):  
Kevin T. Chaung ◽  
Connor O’Brien ◽  
Nghiem B. Ha ◽  
Nghia H. Nguyen ◽  
Huy N. Trinh ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Alternative Therapies ◽  
Partial Virological Response

Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B

Digestion ◽  
2013 ◽  
Vol 87 (3) ◽  
pp. 196-203 ◽  
Author(s):  
Young Eun Chon ◽  
Jun Yong Park ◽  
Sang Hoon Ahn ◽  
Do Young Kim ◽  
Kwang-Hyub Han ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Rescue Therapy ◽  
Partial Virological Response

Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B

2011 ◽  
Vol 16 (4) ◽  
pp. 469-477 ◽  
Author(s):  
Young Eun Chon ◽  
Seung Up Kim ◽  
Chun Kyon Lee ◽  
Jeong Heo ◽  
Ja Kyung Kim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Treatment Naïve ◽  
Partial Virological Response

scholarly journals Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response

2015 ◽  
Vol 59 (9) ◽  
pp. 5348-5356 ◽  
Author(s):  
Hyun Woong Lee ◽  
Jae-Cheol Kwon ◽  
In Soo Oh ◽  
Hye Young Chang ◽  
Young Joo Cha ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Hbeag Seroconversion ◽  
Hbv Dna ◽  
Duration Of Treatment ◽  
Genotypic Resistance ◽  
Treatment Naïve ◽  
Partial Virological Response

ABSTRACTThe aims of this study were to investigate the efficacy of prolonged entecavir (ETV) therapy in treatment-naive chronic hepatitis B (CHB) patients and to determine whether continuous ETV therapy is feasible to achieve HBeAg seroconversion, particularly in patients with partial virological response (PVR). A total of 142 treatment-naive patients with CHB were enrolled. The mean duration of treatment was 65 (range, 26 to 90) months, and 86 patients (60.6%) were HBeAg positive. PVR was defined as detectable hepatitis B virus (HBV) DNA (>116 copies/ml) at year 1. The cumulative incidence of virological response (VR) increased from 54.9% at year 1 to 98.2% at year 7. HBeAg positivity (odds ratio [OR], 4.146;P= 0.001) and initial alanine aminotransferase (ALT) (OR, 0.997;P= 0.004) were independent risk factors for PVR. Among the 64 patients with PVR, 47 patients (73.4%) achieved VR within 4 years after prolonged ETV therapy without treatment adaptation. Three patients (2.1%) experienced virological breakthrough and HBV variants with genotypic resistance. The cumulative rate of HBeAg seroconversion was significantly higher in the patients with VR than in the patients with PVR (P= 0.018). None of the PVR patients with HBV DNA at ≥5,000 copies/ml at year 1 ever experienced HBeAg seroconversion. Multivariate analysis identified VR at year 1 as the only determinant of HBeAg seroconversion (hazard ratio [HR], 3.009;P= 0.010). In conclusion, although there were patients with PVR, prolonged ETV therapy showed excellent VR, with only 2.1% emergence of viral resistance during a 7-year follow-up. However, to achieve HBeAg seroconversion, drug modification is needed for HBeAg-positive patients with PVR (especially those with HBV DNA at ≥5,000 copies/ml at year 1).

Sign in / Sign up

Export Citation Format

Share Document